פתחים סמויים מהעין

SCLN started with an Outperform at RBC; target $9 (5.53 )

RBC initiates coverage of SciClone Pharma with an Outperform rating and $9 target; firm says the Hepatitis C (H.C.V.) mkt is large and under-served, and if the co's Zadaxin treatment is approved, it will be one of the first products specifically indicated for the re-treatment of H.C.V. non-responders; based on U.S. approval in 2H06, they believe Zadaxin product sales could reach $300 mln in 2008 from the H.C.V. indication alone, and could ultimately peak in excess of $400 mln. Firm also notes that Zadaxin has an established commercial history in over 30 countries for various antiviral and oncological indications, and has a good safety profile.